Novel tight-binding inhibitory factor-κB kinase (IKK-2) inhibitors demonstrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation

Journal of Pharmacology and Experimental Therapeutics

Volumn 330, Issue 2, 2009, Pages 377-388

  Sommers, Cynthia D ^a   Thompson, Janice M ^a   Guzova, Julia A ^a   Bonar, Sheri L ^a   Rader, Randall K ^a   Mathialagan, Sumathy ^a   Venkatraman, Neetu ^a   Holway, Vicky Walker ^b   Kahn, Larry E ^a   Hu, George ^a   Garner, Debra S ^a   Huang, Horng Chih ^a   Chiang, Po Chang ^a   Schindler, John F ^a   Hu, Yiding ^a   Meyer, Debra M ^a   Kishore, Nandini N ^a  

^a PFIZER INC   (United States)

^b Pfizer Inc ^*

Author keywords

[No Author keywords available]

Indexed keywords

8 [2 [3,4 BIS(HYDROXYMETHYL) 3,4 DIMETHYLPYRROLIDIN 1 YL] 5 CHLOROISONICOTINAMIDE] 1 (4 FLUOROPHENYL) 4,5 DIHYDRO 1H BENZ[G]INDAZOLE 3 CARBOXAMIDE; 8 [5 CHLORO 2 (4 METHYLPIPERAZIN 1 YL)ISONICOTINAMIDO] 1 (4 FLUOROPHENYL) 4,5 DIHYDRO 1H BENZ[G]INDAZOLE 3 CARBOXAMIDE; FLUTICASONE PROPIONATE; I KAPPA B KINASE; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PF 184; PHA 408; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MALE; MAXIMUM PLASMA CONCENTRATION; NEUTROPHILIA; NONHUMAN; PRIORITY JOURNAL; RAT; RESPIRATORY TRACT INFLAMMATION;

ADMINISTRATION, ORAL; ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; I-KAPPA B KINASE; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOCYTES, MONONUCLEAR; LUNG DISEASES; MALE; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; RATS;

EID: 67651024123     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.147538     Document Type: Article

References (38)

1. Adcock IM, Chung KF, Caramori G, and Ito K (2006) Kinase inhibitors and airway inflammation. Eur J Pharmacol 533:118-132.
2. Alexis N, Eldridge M, Reed W, Bromberg P, and Peden DB (2001) CD14-dependent airway neutrophil response to inhaled LPS: role of atopy. J Allergy Clin Immunol 107:31-35. (Pubitemid 32105240)
3. Baldwin AS Jr (2001) Series Introduction: the transcription factor NF-κB and human disease. J Clin Invest 107:3-6.
4. Barnes PJ (2004a) Alveolar macrophages as orchestrators of COPD. COPD 1:59-70.
5. Barnes PJ (2004b) Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 56:515-548. (Pubitemid 39658462)
6. Barnes PJ and Hansel TT (2004) Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 364:985-996. (Pubitemid 39208462)
7. Barnes PJ (2005) Targeting histone deacetylase 2 in chronic obstructive pulmonary disease treatment. Expert Opin Ther Targets 9:1111-1121. (Pubitemid 41762867)
8. Barnes PJ (2006a) Corticosteroids: the drugs to beat. Eur J Pharmacol 533:2-14.
9. Barnes PJ (2006b) Novel signal transduction modulators for the treatment of airway diseases. Pharmacol Ther 109:238-245.
10. Birrell MA, McCluskie K, Wong S, Donnelly LE, Barnes PJ, and Belvisi MG (2005a) Reservatrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-κB- independent mechanism. FASEB J 19:840-841. (Pubitemid 40617402)
11. Birrell MA, Hardaker E, Wong S, McCluskie K, Catley M, De Alba J, Newton R, Haj-Yahia S, Pun KT, Watts CJ, et al. (2005b) IκB kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma. Am J Respir Crit Care Med 172:962-971. (Pubitemid 41476532)
12. Birrell MA, Wong S, Hardaker EL, Catley MC, McCluskie K, Collins M, Haj-Yahia S, and Belvisi MG (2006) IκB kinase-2-independent and -dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic. Mol Pharmacol 69:1791-1800. (Pubitemid 43894295)
13. Bonizzi G and Karin M (2004) The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25:280-288. (Pubitemid 38610351)
14. Branger J, van den Blink B, Weijer S, Madwed J, Bos CL, Gupta A, Yong CL, Polmar SH, Olszyna DP, Hack CE, et al. (2002) Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 168:4070-4077. (Pubitemid 34298414)
15. Caramori G, Romagnoli M, Casolari P, Bellettato C, Casoni G, Boschetto P, Chung KF, Barnes PJ, Adcock IM, Ciaccia A, et al. (2003) Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. Thorax 58:348-351. (Pubitemid 36411423)
16. Catley MC, Sukkar MB, Chung KF, Jaffee B, Liao SM, Coyle AJ, Haddad el-B, Barnes PJ, and Newton R (2006) Validation of the anti-inflammatory properties of small-molecule IκB kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle. Mol Pharmacol 70:697-705.
17. Corteling R, Wyss D, and Trifilieff A (2002) In vivo models of lung neutrophil activation. Comparison of mice and hamsters. BMC Pharmacol 2:1. (Pubitemid 38729243)
18. Culpitt SV, Rogers DF, Shah P, De Matos C, Russell RE, Donnelly LE, and Barnes PJ (2003) Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167:24-31. (Pubitemid 36015913)
19. Di Stefano A, Caramori G, Oates T, Capelli A, Lusuardi M, Gnemmi I, Ioli F, Chung KF, Donner CF, Barnes PJ, et al. (2002) Increased expression of nuclear factor-κB in bronchial biopsies from smokers and patients with COPD. Eur Respir J 20: 556-563. (Pubitemid 35050145)
20. Everhart MB, Han W, Sherrill TP, Arutiunov M, Polosukhin VV, Burke JR, Sadikot RT, Christman JW, Yull FE, and Blackwell TS (2006) Duration and intensity of NF-κB activity determine the severity of endotoxin-induced acute lung injury. J Immunol 176:4995-5005.
21. Hart LA, Krishnan VL, Adcock IM, Barnes PJ, and Chung KF (1998) Activation and localization of transcription factor, nuclear factor-kB, in asthma. Am J Respir Crit Care Med 158:1585-1592. (Pubitemid 28536624)
22. Ito K, Lim S, Caramori G, Chung KF, Barnes PJ, and Adcock IM (2001) Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J 15:1110-1112.
23. Keatings VM and Barnes PJ (1997) Granulocyte activation markers in induced sputum: Comparison between chronic obstructive pulmonary disease, asthma and normal subjects. Am J Respir Crit Care Med 155:449-453. (Pubitemid 27085784)
24. Kishore N, Sommers C, Mathialagan S, Guzova J, Yao M, Hauser S, Huynh K, Bonar S, Mielke C, Albee L, et al. (2003) A selective IKK-2 inhibitor blocks NF-κB-dependent gene expression in interleukin-1β-stimulated synovial fibroblasts. J Biol Chem 278:32861-32871. (Pubitemid 37055728)
25. Lacoste JY, Bousquet J, Chanez P, Van Vyve T, Simony-Lafontaine J, Lequeu N, Vic P, Enander I, Godard P, and Michel FB (1993) Eosinophilic and Neutrophilic Inflammation in asthma, chronic bronchitis and chronic obstructive pulmonary disease. J Allergy Clin Immunol 92:537-548. (Pubitemid 23317079)
26. Maris NA, de Vos AF, Dessing MC, Spek CA, Lutter R, Jansen HM, van der Zee JS, Bresser P, and van der Poll T (2005) Antiinflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers. Am J Resp Crit Care Med 172:878-884. (Pubitemid 41369072)
27. Matsuda N, Hattori Y, Jesmin S, and Gando S (2005) Nuclear factor-κB decoy oligodeoxynucleotides prevent acute lung injury in mice with cecal ligation and puncture-induced sepsis. Mol Pharmacol 67:1018-1025. (Pubitemid 40410404)
28. Mbalaviele G, Sommers CD, Bonar SL, Mathialagan S, Schindler JF, Guzova JA, Shaffer AF, Melton MA, Christine LJ, Tripp CS, et al. (2009) A novel, highly selective, tight-binding IκB kinase-2 (IKK-2) inhibitor: a tool to correlate IKK-2 activity to the fate and functions of the components of the NF-κB pathway in arthritis relevant cells and animal models. J Pharmacol Exp Ther 329:14-25.
29. Newton R, Holden NS, Catley MC, Oyelusi W, Leigh R, Proud D, and Barnes PJ (2007) Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule IκB kinase inhibitors. J Pharmacol Exp Ther 321:734-742. (Pubitemid 46624511)
30. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, and Hurd SS (2001) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Resp Crit Care Med 163:1256-1276.
31. Poynter ME, Irvin CG, and Janssen-Heininger YMW (2003) A prominent role for airway epithelial NF-κB activation in lipopolysaccharide-induced airway inflammation. J Immunol 170:6257-6265. (Pubitemid 36682611)
32. Rohatagi S, Appajosyula S, Derendorf H, Szefler S, Nave R, Zech K, and Banerji D (2004) Risk-benefit value of inhaled glucocorticoids: A pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol 44:37-47. (Pubitemid 38005092)
33. Skerrett SJ, Liggitt HD, Hajjar AM, Ernst RK, Miller SI, and Wilson CB (2004) Respiratory epithelial cells regulate lung inflammation in response to inhaled endotoxin. Am J Physiol Lung Cell Mol Physiol 287:L143-L152.
34. Sorkness RL, Remus JL, and Rosenthal LA (2004) Systemic and pulmonary effects of fluticasone administered through a metered-dose inhaler in rats. J Allergy Clin Immunol 114:1027-1032.
35. Walters MJ, Paul-Clark MJ, McMaster SK, Ito K, Adcock IM, and Mitchell JA (2005) Cigarette smoke activates human monocytes by an oxidant-AP-1 signaling pathway: Implications for steroid resistance. Mol Pharmacol 68:1343-1353. (Pubitemid 41539990)
36. Wen D, Nong Y, Morgan JG, Gangurde P, Bielecki A, Dasilva J, Keaveney M, Cheng H, Fraser C, Schopf L, et al. (2006) A selective small molecule IκB kinase β inhibitor blocks nuclear factor κB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells. J Pharmacol Exp Ther 317:989-1001. (Pubitemid 43764101)
37. Yang SR, Chida AS, Bauter MR, Shafiq N, Seweryniak K, Maggirwar SB, Kilty I, and Rahman I (2006) Cigarette smoke induces proinflammatory cytokine release by activation of NF-κB and posttranslational modifications of histone deacetylase in macrophages. Am J Physiol Lung Cell Mol Physiol 291:L46-L57.
38. Ziegelbauer K, Gantner F, Lukacs NW, Berlin A, Fuchikami K, Niki T, Sakai K, Inbe H, Takeshita K, Ishimori M, et al. (2005) A selective novel low-molecular-weight inhibitor of IκB kinase-β (IKK-β) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br J Pharmacol 145:178-192. (Pubitemid 40756522)